Why the study?
Does MnCl2 infusion enhance canine myocardium and delineate ischemic areas on MRI?
Does MnCl2 infusion enhance canine myocardium and delineate ischemic areas on MRI?
MnCl2 acts as an intracellular contrast agent that enhances normal canine myocardium and delineates ischemic zones on MRI without adverse cardiac effects at optimal doses.
MnCl2 enhances ischemic delineation on canine MRI at optimal dose; leaves open translation to human imaging.
The ability of MnCl2 to enhance canine myocardium and to delineate ischemic areas is demonstrated. A dose-response curve was measured using T1 weighted images in 11 dogs. MnCl2 (36, 113, 360, and 3600 micromol) was infused over a period of 3 min. Signal intensity increased linearly with MnCl2 dose. At 113 micromol ( approximately 10 micromol/kg) the steady-state increase in intensity averaged 212 +/- 34%. No significant physiologic effects due to the infused MnCl2 were detected except at the highest dose where there was a cardiac depressive effect. Ischemia was induced by occluding the left anterior descending coronary artery in 5 dogs. At an infused dose of 113 micromol, MnCl2 clearly demarcated the ischemic zone during coronary occlusion. Contrast enhancement in the ischemic zone was less than 30% compared with normal tissue (P < 0.03). In conclusion, the intracellular contrast agent MnCl2 enhances the canine heart and shows promise in detecting ischemia at doses that do not cause adverse cardiac effects.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: